After CVS Health (CVS) announced that it has added four new board members following discussions with Glenview Capital, Evercore ISI says the board additions will “bulk up the number of healthcare and technology members” of CVS’s board, which “should add comfort to investors regarding the recovery pathway for HCB as well as the longer-term strategic outlook.” Following the board news as well as CVS’s recent earnings results and revised estimates, the firm says its refreshed sum-of-the-parts analysis “points to CVS being undervalued” and Evercore maintains an Outperform rating and $75 price target on the shares.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- CVS Health Adds Board Members to Pacify Glenview
- Early notable gainers among liquid option names on November 18th
- Morning Movers: Liberty Energy, Tesla up after President-elect Trump alliance
- CVS Health Expands Board with Strategic Appointments
- CVS Health appoints four new directors following agreement with Glenview
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
